The Asia Pacific Cancer Gene Therapy Market would witness market growth of 23.2% CAGR during the forecast period (2022-2028).
An increase in financing for R&D in cancer gene therapy activities, as well as an increase in the occurrence of cancer, are two significant reasons driving the market's expansion. Furthermore, favorable government laws for therapy are expected to promote numerous prospects that would boost Cancer Gene Therapy Market over the forecast period. Furthermore, the risk of cancer gene therapy is reduced since a new gene introduced will integrate into the patient's genome and continue to operate without interfering with the functions of existing genes. However, the high cost of gene therapy, as well as undesired immune reactions, are likely to restrain the growth of the cancer gene therapy market.
The rise in cancer prevalence, ethical acceptability of gene therapy for cancer treatment, and progress in this discipline are some of the growth catalysts for the industry. In addition, the advantages of cancer gene therapy over conventional cancer medicines, as well as an increase in government backing and biotechnology financing that stimulates cancer gene therapy R&D, all contribute to the growth of the market.
Some of the growth catalysts for the regional market are an increase in the prevalence rate of cancer, an increase in a government initiative to develop healthcare infrastructure, and an increase in the number of individuals prone to various chronic diseases. In addition, approval and introduction of cancer gene therapy products might have a favorable impact on market expansion in developed countries like Japan, Australia, and New Zealand.
The growing healthcare infrastructure and increased government initiatives would help the regional market players to increase their offerings and procure maximum revenue share. The region's healthcare infrastructure is improving as people's disposable incomes rise in emerging nations, leading to an increase in the affordability of novel treatment choices. Furthermore, countries such as Korea and India have a huge patient pool. Hence, these aspects are estimated to open new growth avenues for the players operating in the regional Cancer Gene Therapy Market during the forecasting period.
The China market dominated the Asia Pacific Cancer Gene Therapy Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $428.1 million by 2028. The Japan market is estimated to grow at a CAGR of 22.5% during (2022 - 2028). Additionally, The India market would witness a CAGR of 24% during (2022 - 2028).
Based on Therapy, the market is segmented into Gene Induced Immunotherapy, Oncolytic Virotherapy, and Gene Transfer. Based on End User, the market is segmented into Hospitals, Diagnostic centers and Research Institutes. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Cancer Gene Therapy Market is Projected to reach USD 5 Billion by 2028, at a CAGR of 21.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, GlaxoSmithKline PLC (GSK), Amgen, Inc., Bristol Myers, Squibb Company, Karyopharm Therapeutics, Inc., Gilead Sciences, Inc., Adaptimmune Limited, Genelux Corporation, and Sarepta Therapeutics, Inc
Scope of the Study
Market Segments Covered in the Report:
By Therapy
- Gene Induced Immunotherapy
- Oncolytic Virotherapy, and
- Gene Transfer
By End User
- Hospitals
- Diagnostic centers
- Research Institutes
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Novartis AG
- GlaxoSmithKline PLC (GSK)
- Amgen, Inc.
- Bristol Myers Squibb Company
- Karyopharm Therapeutics, Inc.
- Gilead Sciences, Inc.
- Adaptimmune Limited
- Genelux Corporation
- Sarepta Therapeutics, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Cancer Gene Therapy Market, by Therapy
1.4.2 Asia Pacific Cancer Gene Therapy Market, by End User
1.4.3 Asia Pacific Cancer Gene Therapy Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Asia Pacific Cancer Gene Therapy Market by Therapy
3.1 Asia Pacific Gene Induced Immunotherapy Market by Country
3.2 Asia Pacific Oncolytic Virotherapy Market by Country
3.3 Asia Pacific Gene Transfer Market by Country
Chapter 4. Asia Pacific Cancer Gene Therapy Market by End User
4.1 Asia Pacific Hospitals Market by Country
4.2 Asia Pacific Diagnostic centers Market by Country
4.3 Asia Pacific Research Institutes Market by Country
Chapter 5. Asia Pacific Cancer Gene Therapy Market by Country
5.1 China Cancer Gene Therapy Market
5.1.1 China Cancer Gene Therapy Market by Therapy
5.1.2 China Cancer Gene Therapy Market by End User
5.2 Japan Cancer Gene Therapy Market
5.2.1 Japan Cancer Gene Therapy Market by Therapy
5.2.2 Japan Cancer Gene Therapy Market by End User
5.3 India Cancer Gene Therapy Market
5.3.1 India Cancer Gene Therapy Market by Therapy
5.3.2 India Cancer Gene Therapy Market by End User
5.4 South Korea Cancer Gene Therapy Market
5.4.1 South Korea Cancer Gene Therapy Market by Therapy
5.4.2 South Korea Cancer Gene Therapy Market by End User
5.5 Singapore Cancer Gene Therapy Market
5.5.1 Singapore Cancer Gene Therapy Market by Therapy
5.5.2 Singapore Cancer Gene Therapy Market by End User
5.6 Malaysia Cancer Gene Therapy Market
5.6.1 Malaysia Cancer Gene Therapy Market by Therapy
5.6.2 Malaysia Cancer Gene Therapy Market by End User
5.7 Rest of Asia Pacific Cancer Gene Therapy Market
5.7.1 Rest of Asia Pacific Cancer Gene Therapy Market by Therapy
5.7.2 Rest of Asia Pacific Cancer Gene Therapy Market by End User
Chapter 6. Company Profiles
6.1 Novartis AG
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.2 GlaxoSmithKline PLC (GSK)
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.3 Amgen, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Regional Analysis
6.3.4 Research & Development Expenses
6.4 Bristol Myers Squibb Company
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expenses
6.5 Karyopharm Therapeutics, Inc.
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Research & Development Expense
6.6 Gilead Sciences, Inc.
6.6.1 Company overview
6.6.2 Financial Analysis
6.6.3 Research & Development Expenses
6.7 Adaptimmune Limited
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Research & Development Expenses
6.8 Genelux Corporation
6.8.1 Company Overview
6.9 Sarepta Therapeutics, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Research & Development Expenses
TABLE 1 Asia Pacific Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 2 Asia Pacific Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 3 Asia Pacific Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 4 Asia Pacific Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 5 Asia Pacific Gene Induced Immunotherapy Market by Country, 2018 - 2021, USD Million
TABLE 6 Asia Pacific Gene Induced Immunotherapy Market by Country, 2022 - 2028, USD Million
TABLE 7 Asia Pacific Oncolytic Virotherapy Market by Country, 2018 - 2021, USD Million
TABLE 8 Asia Pacific Oncolytic Virotherapy Market by Country, 2022 - 2028, USD Million
TABLE 9 Asia Pacific Gene Transfer Market by Country, 2018 - 2021, USD Million
TABLE 10 Asia Pacific Gene Transfer Market by Country, 2022 - 2028, USD Million
TABLE 11 Asia Pacific Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 12 Asia Pacific Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 13 Asia Pacific Hospitals Market by Country, 2018 - 2021, USD Million
TABLE 14 Asia Pacific Hospitals Market by Country, 2022 - 2028, USD Million
TABLE 15 Asia Pacific Diagnostic centers Market by Country, 2018 - 2021, USD Million
TABLE 16 Asia Pacific Diagnostic centers Market by Country, 2022 - 2028, USD Million
TABLE 17 Asia Pacific Research Institutes Market by Country, 2018 - 2021, USD Million
TABLE 18 Asia Pacific Research Institutes Market by Country, 2022 - 2028, USD Million
TABLE 19 Asia Pacific Cancer Gene Therapy Market by Country, 2018 - 2021, USD Million
TABLE 20 Asia Pacific Cancer Gene Therapy Market by Country, 2022 - 2028, USD Million
TABLE 21 China Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 22 China Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 23 China Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 24 China Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 25 China Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 26 China Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 27 Japan Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 28 Japan Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 29 Japan Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 30 Japan Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 31 Japan Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 32 Japan Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 33 India Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 34 India Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 35 India Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 36 India Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 37 India Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 38 India Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 39 South Korea Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 40 South Korea Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 41 South Korea Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 42 South Korea Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 43 South Korea Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 44 South Korea Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 45 Singapore Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 46 Singapore Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 47 Singapore Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 48 Singapore Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 49 Singapore Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 50 Singapore Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 51 Malaysia Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 52 Malaysia Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 53 Malaysia Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 54 Malaysia Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 55 Malaysia Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 56 Malaysia Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 57 Rest of Asia Pacific Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 58 Rest of Asia Pacific Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 59 Rest of Asia Pacific Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 60 Rest of Asia Pacific Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 61 Rest of Asia Pacific Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 62 Rest of Asia Pacific Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 63 Key Information – Novartis AG
TABLE 64 Key Information – GlaxoSmithKline PLC (GSK)
TABLE 65 Key Information – Amgen, Inc.
TABLE 66 Key Information – Bristol Myers Squibb Company
TABLE 67 key Information – Karyopharm Therapeutics, Inc.
TABLE 68 Key Information – Gilead Sciences, Inc.
TABLE 69 Key information – Adaptimmune Limited
TABLE 70 Key Information – Genelux Corporation
TABLE 71 key information – Sarepta Therapeutics, Inc.
List of Figures
FIG 1 Methodology for the research
FIG 2 Recent strategies and developments: Novartis AG
FIG 3 Recent strategies and developments: Bristol Myers Squibb Company